STRATFORD, N.J.--(BUSINESS WIRE)--Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced the appointment of Dr. Mert Sahin as Chief Executive Officer.

STRATFORD，N.J.-（BUSINESS WIRE）-神经退行性疾病诊断测试开发和商业化的创新者Durin Technologies，Inc.今天宣布任命Mert Sahin博士为首席执行官。

Dr. Sahin is a highly accomplished business executive with an impressive track record of success in the life sciences sector. He brings to Durin more than 20 years of experience in life sciences, pharmaceuticals, and medical devices, where he has demonstrated expertise in formulating and executing strategic go-to-market plans resulting in exceptional growth..

Sahin博士是一位杰出的业务高管，在生命科学领域取得了令人瞩目的成功记录。他在生命科学，制药和医疗器械方面拥有20多年的经验，在那里他展示了制定和执行战略上市计划的专业知识，从而实现了卓越的增长。。

Dr. Sahin’s previous roles include executive positions at GE Healthcare, where he led marketing for its Imaging Business in the U.S. & Canada and was instrumental in growing the Molecular Imaging Business. He has held various commercial roles at Roche Diagnostics, Eurofins Genomics, Thermo Fisher Scientific and Dalan Animal Health.

Sahin博士之前的职责包括GE Healthcare的执行职位，他在美国和加拿大领导其成像业务的营销，并有助于发展分子成像业务。他在Roche Diagnostics，Eurofins Genomics，Thermo Fisher Scientific和Dalan Animal Health担任过各种商业角色。

Dr. Sahin also co-founded Boston BioProcess, which helps alternative protein ingredient companies transition from the lab to commercial scale. He holds a PhD in Cell Biology from University of Hamburg, Germany..

Sahin博士还共同创立了Boston BioProcess，该公司帮助替代蛋白质成分公司从实验室过渡到商业规模。他拥有德国汉堡大学细胞生物学博士学位。。

Dr. Sahin will lead Durin Technologies as it commercializes its novel diagnostic tests for Alzheimer’s and Parkinson’s diseases, and develops its next generation of diagnostic tests for other diseases and disorders at their earliest stages.

Sahin博士将领导Durin技术，因为它将其针对阿尔茨海默氏症和帕金森病的新型诊断测试商业化，并在其早期阶段开发其针对其他疾病和病症的下一代诊断测试。

Dr. Robert Nagele, Durin’s Founder and Chief Scientific Officer said, “Dr. Sahin’s team-centric, lead-by-example leadership style and innovative approach to fostering growth make him an excellent fit for Durin's aggressive growth plans. We're confident that his strategic vision, expertise, and determination will propel the company forward and allow Durin to seize the significant market opportunities available.”.

Durin的创始人兼首席科学官Robert Nagele博士说，“Sahin博士以团队为中心，以身作则的领导风格和促进成长的创新方法，使他非常适合Durin的积极成长计划。我们相信他的战略愿景，专业知识和决心将推动公司前进，并允许Durin抓住可用的重要市场机会“。

“I am excited to join Durin, which will quickly become the innovation leader in neurodegenerative disease diagnostics,” said Dr. Sahin. “I look forward to working closely with the team to advance Durin to the next stage of its commercial success.”

Sahin博士说：“我很高兴加入Durin，Durin将很快成为神经退行性疾病诊断领域的创新领导者。”。“我期待与团队密切合作，推动杜林进入商业成功的下一阶段。”

About Durin Technologies, Inc.

关于杜林科技有限公司。

Durin Technologies develops non-invasive, easy access diagnostic tests for the most prevalent and devastating neurodegenerative disorders, including Alzheimer's and Parkinson's diseases.​ Its rapid-result, high-accuracy DuritectTM diagnostic tests make early detection and monitoring of disease progression possible – in a decade or more prior to symptoms in some cases.

Durin技术为最普遍和最具破坏性的神经退行性疾病（包括阿尔茨海默氏病和帕金森氏病）开发了非侵入性，易于获取的诊断测试。​ 其快速的结果，高精度的DuritectTM诊断测试使疾病进展的早期发现和监测成为可能-在某些情况下，在症状出现之前的十年或更长时间内。

Durin’s first two tests – for Alzheimer's and Parkinson’s – will come to market in 2024, followed by tests for other diseases.​ The company’s groundbreaking science creates a scalable platform for diagnostic tests that will extend beyond the multi-billion-dollar neurodegenerative diagnostics market into the much larger, broader disease diagnostic market.​.

Durin的前两项针对阿尔茨海默氏病和帕金森氏病的测试将于2024年上市，然后针对其他疾病进行测试。​ 该公司开创性的科学为诊断测试创建了一个可扩展的平台，将超越价值数十亿美元的神经退行性诊断市场，进入更大，更广泛的疾病诊断市场。​.

Learn more: durintechnologies.com

了解更多信息：durintechnologies.com